FDA grants fast-track designation for Istesso’s IPF candidate
The therapy has reduced inflammation and supported the remodelling of damaged bone
Read More
Author: John Pinching
Valneva shares positive chikungunya vaccine results
99% of participants retained very high neutralising antibody levels 12 months after treatment
Read More
Merck KGaA’s arpraziquantel validated by European Medicines Agency
Positive scientific opinion by EMA would create pathway for arpraziquantel in African endemic countries
Read More
Healthcare leaders warn about unsustainable pressure on mental health services
Patients and service users routinely struggle to access mental healthcare across the NHS
Read More
Valneva and Pfizer report Lyme disease antibody data
Children and adults have been treated using the Lyme disease antibody candidate VLA15
Read More- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
- BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
